OS and RFS of Bcl-2–immunonegative DLCL patients with Bax-immunonegative and -immunopositive tumors. (A) OS and (B) RFS, comparing Bcl-2–immunonegative patients (n = 85) whose tumors contained (less than 1%) Bax-immunostained malignant cells (n = 7) with those that were Bax-immunopositive (n = 78; P < .05 and <.01, respectively).